BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

June 16, 2014 7:00 AM UTC

BioDelivery Sciences International Inc. (NASDAQ:BDSI) gained $2.36 (24%) to $12.36 last week after FDA approved Bunavail buprenorphine naloxone as maintenance treatment for opioid dependence. BioDelivery said it plans to launch the product late next quarter.

Geron Corp. (NASDAQ:GERN) jumped $0.55 (21%) to $3.15 on Thursday after FDA lifted a partial clinical hold on an investigator-sponsored pilot trial of the company's imetelstat (GRN163L), though the agency is maintaining a full clinical hold on company-sponsored trials of the product. FDA placed the holds in March due to a safety signal of hepatotoxicity in trials of the compound...